Remibrutinib Becomes First On-Label Therapy for Symptomatic Dermographism
Remibrutinib, an oral BTK inhibitor, is the first on-label therapy for symptomatic dermographism. David Cotter, MD, PhD, explains what the label changes for prescribers.
Topic
Symptomatic Dermographism
Topic
Symptomatic Dermographism
FDA Expands Urticaria Drug Indication to Symptomatic Dermographism
The FDA has expanded a urticaria drug's indication to treat symptomatic dermographism, moving a common inducible urticaria into o…
FDA Approves Remibrutinib for Symptomatic Dermographism
The US FDA has approved oral BTK inhibitor remibrutinib for symptomatic dermographism, delivering the first labeled targeted ther…